Westlake Sarah, Jones Matthew, Sharma Krishna D, Xie Jennifer Yanhua
Basic Sciences Department, New York Institute of Technology College of Osteopathic Medicine at Arkansas State University, Jonesboro, AR, USA.
Department of Biological Sciences and Arkansas Biosciences Institute, Arkansas State University, Jonesboro, AR, USA.
eNeurologicalSci. 2022 Jul 2;28:100416. doi: 10.1016/j.ensci.2022.100416. eCollection 2022 Sep.
Diabetic peripheral neuropathy (DPN) is a medical condition that is progressively becoming more prevalent. The underlying cause of DPN is still unknown, although there have been several hypothesized mechanisms. There are current pharmaceutical treatments used to manage the pain, but their efficacy is largely unsatisfactory and are often associated with serious adverse effects. This review will explore the evidence of a new potential target for treating DPN, the ligands for nicotinic acetylcholine receptors (nAChRs), specifically α4ꞵ2 agonists and α9α10 antagonists.
糖尿病周围神经病变（DPN）是一种日益普遍的医学病症。尽管已经有几种假说机制，但DPN的根本原因仍然不明。目前有用于控制疼痛的药物治疗方法，但其疗效大多不尽人意，且常常伴有严重的不良反应。本综述将探讨一种治疗DPN的新潜在靶点——烟碱型乙酰胆碱受体（nAChRs）配体，特别是α4ꞵ2激动剂和α9α10拮抗剂的相关证据。
